Exercise of Share Options and Total Voting Rights

Synairgen plc

30 October 2024

 

 

Synairgen plc

('Synairgen' or the 'Company')

Exercise of Share Options and Total Voting Rights

 

Southampton, UK - 30 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that it has allotted a total of 1,285,722 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by an ex-employee of the Company.

Application has been made to the London Stock Exchange for the 1,285,722 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 5 November 2024.

Following Admission, the total number of Ordinary Shares in issue will be 202,660,697 and the total number of voting rights will therefore be 202,660,697. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further enquiries, please contact:

Synairgen plc

[e-mail]

Tel: + 44 (0) 23 8051 2800

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Nigel Birks - Life Science Specialist Sales

Tel: + 44 (0) 20 7220 0500

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

ICR Healthcare (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

END